What works for one persons body may not be right for another, especially when factors like blood donation, activity levels, and underlying health conditions are involved
Increased concentrations of blood TMAO have a strong link with increased major adverse cardiovascular events and all-cause mortality 13,14
As our understanding of GLP-1 receptor agonists grows, these medications may play an even larger role in treating a wide range of metabolic and obesity-related health issues
Insurance coverage considerations Semaglutide (Ozempic, Wegovy) is FDA-approved for type 2 diabetes and chronic weight management, not specifically for PCOS
The scale of effect is dramatically different
The conversation around GLP1 therapy for adolescents with type 2 diabetes is evolving quickly